Safety of tapering tacrolimus dose in patients with well‐controlled anti‐acetylcholine receptor antibody‐positive myasthenia gravis

Abstract

Tapering of tacrolimus was possible in most patients with well-controlled anti-acetylcholine receptor antibody-positive MG. Early age at onset and a large reduction from maintenance dosage were associated with exacerbation. Reductions ≤1.5 mg/day from the maintenance dosage should be considered for patients with late-onset disease.